MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
